Lawrence G. Lum, MD
Primary Appointment
Professor
Director of Cellular Therapy
Scientific Director of Bone Marrow Transplant
Medicine: Hematology and Oncology
Contact
University of Virginia
West Complex 7191
Charlottesville, VA 22908
Telephone: 434.243.1375
Email: lgl4f@hscmail.mcc.virginia.edu
Education and Training
- BS, Chemistry, University of Redlands
- MD, University of California
Research Summary
Research Interests:
Cancer immunotherapy
Research Summary:
Dr. Lum’s primary focus is enhancing the patient’s immune system to make it a better cancer-killing machine. Cancer immunotherapy works by utilizing a patient’s T cells, which are already programmed to destroy abnormal cells. Grown in the laboratory, the T cells are then directed to target cancer cells. Dr. Lum’s method is unique in how he directs the T cells by linking two antibodies that bind to T cells and tumor cells and form a killing bridge between the two. The development of this targeting platform allows the procedure to be done and adapted quickly to different cancers. Infusions of the targeted T cells create lasting immunity by vaccinating patients against their tumors.
Lab Members
Associate Professor
Regulatory and Facilities Manager
Lab and Research Tech
Clinical Lab Tech
Consultant
Grants and Contracts Administrator
Lab and Research Tech
- Thakur A, Huang M, Lum LG, Bispecific antibody-based therapeutics: Strengths and challenges., 2018; Blood reviews. 32(4) 339-347. PMID: 29482895
- Al-Kadhimi Z, Gul Z, Abidi M, Lum LG, Deol A, Chen W, Jang H, Ozust C, Langston A, Waller E, Uberti J, Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention., 2017; Bone marrow transplantation. 52(9) 1304-1310. PMID: 28581472
- Thakur A, Lum LG, Mittal S, Bispecific Antibody Armed T Cells to Target Cancer Cells., 2017; Methods in molecular biology (Clifton, N.J.). 1722() 117-126. PMID: 29264802
- Modi D, Jang H, Kim S, Surapaneni M, Sankar K, Deol A, Ayash L, Bhutani D, Lum LG, Ratanatharathorn V, Manasa R, Mellert K, Chandrasekar P, Uberti JP, Fluoroquinolone prophylaxis in autologous hematopoietic stem cell transplant recipients., 2017; Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer. 25(8) 2593-2601. PMID: 28365897
- Parajuli P, Anand R, Mandalaparty C, Suryadevara R, Sriranga PU, Michelhaugh SK, Cazacu S, Finniss S, Thakur A, Lum LG, Schalk D, Brodie C, Mittal S, Preferential expression of functional IL-17R in glioma stem cells: potential role in self-renewal., 2016; Oncotarget. 7(5) 6121-35. PMID: 26755664 | PMCID: PMC4868744
- Lum LG, Thakur A, Kondadasula SV, Al-Kadhimi Z, Deol A, Tomaszewski EN, Yano H, Schalk DL, Ayash L, Zonder JA, Uberti JP, Abidi MH, Ratanatharathorn V, Targeting CD138-/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity., 2016; Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 22(5) 869-78. PMID: 26827660
- Thakur A, Lum LG, In Situ immunization by bispecific antibody-targeted T cell therapy in breast cancer., 2016; Oncoimmunology. 5(3) e1055061. PMID: 27141330 | PMCID: PMC4839366
- Gibson HM, Veenstra JJ, Jones R, Vaishampayan U, Sauerbrey M, Bepler G, Lum L, Reyes J, Weise A, Wei WZ, Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination., 2015; Cancer immunology research. 3(7) 777-86. PMID: 25711535 | PMCID: PMC4491035
- Mallhi K, Lum LG, Schultz KR, Yankelevich M, Hematopoietic cell transplantation and cellular therapeutics in treating childhood malignancies., 2014; Pediatric clinics of North America. 62(1) 257-73. PMID: 25435122